secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtaiBeckley Inc. (ATAI)
CIK:        0002081043
Form:       8-K
Filed at:   2026-07-16T11:27:30+00:00
Accession:  0001140361-26-028604
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtaiBeckley to be acquired by Eli Lilly for $6.75/share plus CVRs up to $2.50/share
--------------------------------------------------------------------------------

- Merger consideration: $6.75 per share cash plus one CVR per share with potential milestone payments up to $2.50 per share.
- CVR milestones: $1.00 for VLS-01 Phase 3 start, $0.50 for BPL-003 US approval/DEA rescheduling, $1.00 for VLS-01 US approval/DEA rescheduling.
- Termination fee of $104.3M payable by AtaiBeckley under certain conditions; no-shop with fiduciary out.
- Support agreements with directors, officers, and Apeiron Investment Group to vote in favor.
- Conditions include stockholder approval, HSR clearance, no MAE; expected close within 6-9 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2081043/000114036126028604/0001140361-26-028604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2081043/000114036126028604/ef20078103_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-028604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer